Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by GUILLERMO GARCIA-MANERO and SIMONA COLLA.
GUILLERMO GARCIA-MANERO
Connection Strength
4.295
SIMONA COLLA
  1. Hematopoietic stem cells with granulo-monocytic differentiation state overcome venetoclax sensitivity in patients with myelodysplastic syndromes. Nat Commun. 2024 Mar 18; 15(1):2428.
    View in: PubMed
    Score: 0.245
  2. Targeting DNA2 overcomes metabolic reprogramming in multiple myeloma. Nat Commun. 2024 Feb 08; 15(1):1203.
    View in: PubMed
    Score: 0.244
  3. Oral decitabine plus cedazuridine and venetoclax in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: a single-centre, phase 1/2 study. Lancet Haematol. 2024 Mar; 11(3):e186-e195.
    View in: PubMed
    Score: 0.243
  4. IL-1?-mediated inflammatory signaling drives ineffective erythropoiesis in early-stage myelodysplastic syndromes. bioRxiv. 2023 Sep 30.
    View in: PubMed
    Score: 0.238
  5. Targeting MCL1-driven anti-apoptotic pathways to overcome hypomethylating agent resistance in RAS -mutated chronic myelomonocytic leukemia. bioRxiv. 2023 Apr 08.
    View in: PubMed
    Score: 0.230
  6. Targeting DNA2 Overcomes Metabolic Reprogramming in Multiple Myeloma. bioRxiv. 2023 Feb 22.
    View in: PubMed
    Score: 0.228
  7. Emerging treatments for myelodysplastic syndromes: Biological rationales and clinical translation. Cell Rep Med. 2023 02 21; 4(2):100940.
    View in: PubMed
    Score: 0.227
  8. Targeting the EIF2AK1 Signaling Pathway Rescues Red Blood Cell Production in SF3B1-Mutant Myelodysplastic Syndromes With Ringed Sideroblasts. Blood Cancer Discov. 2022 11 02; 3(6):554-567.
    View in: PubMed
    Score: 0.223
  9. Azacitidine plus venetoclax in patients with high-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: phase 1 results of a single-centre, dose-escalation, dose-expansion, phase 1-2 study. Lancet Haematol. 2022 Oct; 9(10):e756-e765.
    View in: PubMed
    Score: 0.221
  10. Cooperation between KDM6B overexpression and TET2 deficiency in the pathogenesis of chronic myelomonocytic leukemia. Leukemia. 2022 08; 36(8):2097-2107.
    View in: PubMed
    Score: 0.217
  11. Author Correction: Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy. Nat Med. 2022 May; 28(5):1097.
    View in: PubMed
    Score: 0.215
  12. Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy. Nat Med. 2022 03; 28(3):557-567.
    View in: PubMed
    Score: 0.213
  13. Hematopoiesis under telomere attrition at the single-cell resolution. Nat Commun. 2021 11 25; 12(1):6850.
    View in: PubMed
    Score: 0.209
  14. NPM1 mutations define a specific subgroup of MDS and MDS/MPN patients with favorable outcomes with intensive chemotherapy. Blood Adv. 2019 03 26; 3(6):922-933.
    View in: PubMed
    Score: 0.174
  15. KDM6B overexpression activates innate immune signaling and impairs hematopoiesis in mice. Blood Adv. 2018 10 09; 2(19):2491-2504.
    View in: PubMed
    Score: 0.168
  16. ILF2 Is a Regulator of RNA Splicing and DNA Damage Response in 1q21-Amplified Multiple Myeloma. Cancer Cell. 2017 07 10; 32(1):88-100.e6.
    View in: PubMed
    Score: 0.154
  17. Impact of achievement of complete cytogenetic response on outcome in patients with myelodysplastic syndromes treated with hypomethylating agents. Am J Hematol. 2017 Apr; 92(4):351-358.
    View in: PubMed
    Score: 0.150
  18. PDE4 Differential Expression Is a Potential Prognostic Factor and Therapeutic Target in Patients With Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia. Clin Lymphoma Myeloma Leuk. 2016 08; 16 Suppl:S67-73.
    View in: PubMed
    Score: 0.145
  19. Down-regulation of EZH2 expression in myelodysplastic syndromes. Leuk Res. 2016 May; 44:1-7.
    View in: PubMed
    Score: 0.140
  20. Analysis of class I and II histone deacetylase gene expression in human leukemia. Leuk Lymphoma. 2015; 56(12):3426-33.
    View in: PubMed
    Score: 0.133
  21. Telomere dysfunction drives aberrant hematopoietic differentiation and myelodysplastic syndrome. Cancer Cell. 2015 May 11; 27(5):644-57.
    View in: PubMed
    Score: 0.133
  22. Impact of the number of mutations in survival and response outcomes to hypomethylating agents in patients with myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms. Oncotarget. 2018 Feb 09; 9(11):9714-9727.
    View in: PubMed
    Score: 0.040
  23. Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a case-control study. Lancet Oncol. 2017 01; 18(1):100-111.
    View in: PubMed
    Score: 0.037
  24. Cancer-Associated SF3B1 Hotspot Mutations Induce Cryptic 3' Splice Site Selection through Use of a Different Branch Point. Cell Rep. 2015 Nov 03; 13(5):1033-45.
    View in: PubMed
    Score: 0.034
  25. Downregulation of Protection of Telomeres 1 expression in myelodysplastic syndromes with 7q deletion. Br J Haematol. 2016 Apr; 173(1):161-5.
    View in: PubMed
    Score: 0.033
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.